|
Patent landscape, scope, and claims: |
Scope and Claims Analysis for US Patent 9,732,092: Formula (I) Compounds, Stereoisomers, and HIV Combination Compositions
US 9,732,092 is a US composition-and-compound patent centered on a defined heteroatom-containing core (X = —O—; W = —CHZ2—; Z1/Z2 to a fused “L” motif defined as —C(Ra)2C(Ra)2—) with a tightly bounded aryl substitution pattern (R1 = mono-, di-, or tri-halogen substituted phenyl) and terminal substituent controls (Y1/Y2 = H/C1-3alkyl/C1-3haloalkyl). Claim scope tracks a classic “Markush-style” core plus a small aryl halogen subspace, with further dependent claim narrowing to specific phenyl isomers (including fluorinated phenyls). The later composition claims expand coverage to pharmaceutical formulations and to HIV therapy combinations (including specific HIV drug classes).
What is the scope of US 9,732,092 (claims 1–16) and how broad is Formula (I)?
Answer (scope): Claim 1 covers a family of “compounds of Formula (I)” defined by (i) a fixed linkage framework (X, W, Z4) and (ii) a restricted stereochemical and substituent universe: R1 is a halogenated phenyl with one to three halogens (with enumerated preferred aryl patterns), while Y1/Y2 are each independently limited to hydrogen or small C1-3 substituents (alkyl or haloalkyl). Dependent claims narrow to specific halogen substitution counts and named aryls, then broaden again at the composition layer to HIV-containing regimens through dependent claims 13–16.
How the claim constrains the “core” scaffold
Claim 1 is not a free-form structure claim. It is a “structure formula with variable points,” where several structural elements are hard-coded:
-
X is —O—
Oxygen is fixed as the heteroatom linkage at that position.
-
W is —CHZ2—
The carbon at that position is CH with a substituent link to Z2, fixing an sp3-carbon bearing the Z2 variable.
-
Z1 and Z2, taken together, form —L-
The connection between Z1 and Z2 creates a divalent ring/bridge segment defined as:
- L is —C(Ra)2C(Ra)2—
This is a key structural determinant. It restricts the scaffold to a specific bis-substituted carbon motif with four independently defined Ra substituents.
-
Z4 is —CH2—
This position is fixed as methylene.
How the claim constrains the substituent pattern
-
Y1 and Y2 each independently are hydrogen, C1-3 alkyl or C1-3 haloalkyl.
That is a tight range:
- allowed substituents: H, methyl/ethyl/propyl, and haloalkyl with 1–3 carbons (for example, fluoromethyl, trifluoropropyl, etc. where consistent with “haloalkyl” definition).
-
R1 is phenyl substituted with one, two or three halogens.
R1 must be a phenyl ring that has:
- exactly one halogen (claim 2 narrows further),
- or exactly two halogens (claim 4 narrows further),
- or exactly three halogens (claim 7 narrows further).
-
Each Ra is independently hydrogen, halo, hydroxy or C1-4 alkyl.
This governs the four substituents on the L motif. Ra permits:
- H
- halogens (unspecified type but typically F/Cl/Br/I)
- hydroxy
- C1-4 alkyl (methyl to butyl)
Stereochemistry and salts
Claim 1 includes:
- a compound having Formula (I) or
- a stereoisomer or
- a pharmaceutically acceptable salt thereof.
This gives standard coverage to salt forms and stereoisomeric variants, but it does not expressly include conformational variants beyond stereoisomers.
How do dependent claims narrow the aryl halogen universe (claims 2–9)?
Dependent claims 2–9 create a tiered funnel from general halogenated phenyls to explicitly named fluorinated phenyl patterns.
Claim 2 and 3: mono-halogen phenyl
- Claim 2: R1 substituted with one halogen.
- Claim 3: specific mono-halogen embodiments:
- 4-fluorophenyl or 2-fluorophenyl.
This is a narrow enumerated set for the mono-fluoro case, but note claim 1 still covers “one halogen” beyond fluor if the halogen type is not limited in claim 1. Claim 3 appears to be an explicit subset.
Claim 4 and 5: di-halogen phenyl
-
Claim 4: R1 substituted with two halogens.
-
Claim 5: enumerates preferred di-halogen fluorinated/chlorinated phenyls:
- 2,4-difluorophenyl
- 2,3-difluorophenyl
- 2,6-difluorophenyl
- 3-fluoro-4-chlorophenyl
- 3,4-difluorophenyl
- 2-fluoro-4-chlorophenyl
- 3,5-difluorophenyl
-
Claim 6: one dependent singled-out embodiment:
Claim 7–9: tri-halogen phenyl
- Claim 7: R1 substituted with three halogens.
- Claim 8: enumerates:
- 2,4,6-trifluorophenyl
- 2,3,4-trifluorophenyl
- Claim 9: further selects:
Net effect on claim landscape
The dependent claims indicate that the patent’s prosecuting/focus chemistry prioritized fluorine-rich phenyl rings:
- mono: 2-F and 4-F
- di: multiple difluoro and fluoro-chloro patterns
- tri: trifluoro patterns (not chlorinated tri-halogen exemplars)
From an infringement or freedom-to-operate perspective, the “bright line” risk zone is:
- R1 with the enumerated substitution patterns, especially fluorine placements, plus the fixed core features (X, W, Z1/Z2-to-L motif, Z4).
How do Y1/Y2 variables affect coverage (claim 10)?
- Claim 10: Y1 and Y2 each independently are hydrogen, methyl or trifluoromethyl.
This dependent claim collapses claim 1’s broader Y1/Y2 range (H/C1-3alkyl/C1-3haloalkyl) to an even tighter “H, Me, CF3” selection.
For product design around:
- compounds using Y1/Y2 values outside {H, methyl, CF3} are less likely to fall under claim 10 but still could fall under claim 1 depending on the actual substituents (so claim 10 is narrower than claim 1).
What is the scope of Formula (II-A) (claim 11) and how does it relate to claim 1?
- Claim 11: the compound of claim 1 having Formula (II-A).
Because the text provided does not include the explicit structure of Formula (II-A), the practical scope cannot be decomposed into a set of measurable variable constraints. The functional inference for claim mapping is:
- claim 11 is a subset of claim 1, limited to compounds that also satisfy additional constraints in II-A (typically a specific stereochemistry, ring closure, regiochemistry, or substitution pattern).
For claim strategy, claim 11 likely provides an additional “hook” for particular embodiments that may have been emphasized during examination.
What is claimed for pharmaceutical compositions and HIV combination therapy (claims 13–16)?
Claim 12
- Claim 12: compound of claim 1 selected from a set of listed compounds.
The provided claim excerpt truncates the actual “group consisting of” list. Without the identities of those compounds, exact coverage cannot be enumerated.
Claim 13: baseline composition
- Claim 13: a pharmaceutical composition comprising:
- a compound of claim 1 (or stereoisomer/salt) plus
- a pharmaceutically acceptable carrier/diluent/excipient.
This is standard composition coverage: it is generally broad across formulation types, constrained mainly by inclusion of the claimed active.
Claim 14: combination with one or more additional therapeutic agents
- Claim 14: further comprising one or more additional therapeutic agents.
Claim 15: specific therapeutic area
- Claim 15: the additional therapeutic agents are an anti-human immunodeficiency virus agent.
Claim 16: enumerated HIV classes
- Claim 16: the anti-HIV agent is selected from:
- HIV protease inhibitor
- HIV non-nucleoside inhibitor of reverse transcriptase
- HIV nucleoside inhibitor of reverse transcriptase
- HIV nucleotide inhibitor of reverse transcriptase
- or combinations of the above.
Net effect: The composition claims create a regulatory-use and combination-use infringement pathway:
- A product containing a claimed compound + a labeled HIV class agent could fall within claim 16 even if the HIV agent itself is not structurally related to the claimed compound.
What patents likely exist around US 9,732,092 (landscape dimensions relevant to scope/claims)?
The question asks for “patent landscape,” but only claim text is provided. A complete, accurate landscape requires identifying:
- the patent assignee(s),
- application family (continuations/divisionals),
- related US patents in the same priority chain,
- corresponding WO/Eur/JP/CN filings,
- whether there are Orange Book listings or listed NDA/ANDA references tied to this patent family,
- and whether there are Paragraph IV challenges and litigations tied to the relevant listed drug(s).
Under the operating constraint, no landscape specifics can be produced from the provided record alone.
What can be stated from the claim set itself are the likely landscape “hot zones” that would be targeted by generic or biosimilar style strategies in litigation, licensing, or design-around:
- Core structure coverage (Formula I scaffold) is the primary estate pillar.
- R1 aryl halogen substitution is the main variability leveraged for design-around.
- Y1/Y2 substitution is the second variability lever.
- Salts and stereoisomers broaden the estate without changing core structure.
- Composition/combination claims broaden enforcement into product formulation and co-therapy contexts, including enumerated HIV therapy classes.
What is the actionable claim mapping: which structural changes are most likely to avoid infringement?
Based on the constraint language in claim 1:
High-salience avoidance points
-
Break the fixed scaffold constraints
- If X is changed away from —O— or Z4 is changed away from —CH2—, the compound may fall outside claim 1.
-
Disrupt the L motif formation
- Z1 and Z2 “taken together” forming L = —C(Ra)2C(Ra)2— means the relationship between Z1 and Z2 is crucial. Altering the topology or number of substitutable positions likely moves outside the formula definition.
-
Change W away from —CHZ2—
- Altering that substitution pattern can eliminate coverage.
-
Move R1 outside mono/di/tri halogen phenyl
- Using non-halogen substitutions or altering the degree to zero or four+ halogens is an obvious path.
Ar-closure design-around
- If R1 is constrained to “one, two or three halogens,” then using:
- alkyl-substituted phenyls,
- heteroaryl replacements,
- or aryls with more than three halogens,
could avoid claim 1 depending on whether the formula still satisfies the R1 definition.
Narrow enumerated embodiments
- Claim 3, claim 5/6, and claim 9 enumerate specific R1 substitution patterns. If a product uses aryl halogen patterns not listed in those dependent claims, it may still infringe claim 1 if the pattern still fits “phenyl substituted with one, two or three halogens” under claim 1. The dependent claims mainly help define emphasized subsets.
Composition-level avoidance
- Even if a compound is not within claim 1, composition claims in claim 13–16 require inclusion of “a compound of claim 1.” If the active is outside claim 1, composition infringement is unlikely under these claims.
- If the active is within claim 1, avoiding claim 16 would require changing the co-administered HIV agent class away from the listed categories, where those categories correspond to protease inhibitors, NNRTIs, NRTIs, and Nucleotide inhibitors.
Key takeaways
- US 9,732,092 claim 1 defines a specific heteroatom-containing scaffold with fixed elements (X = —O—, W = —CHZ2—, Z4 = —CH2—, and Z1/Z2 forming L = —C(Ra)2C(Ra)2—) plus variable substituent controls (Y1/Y2 limited to H/C1-3alkyl/C1-3haloalkyl; R1 limited to phenyl mono-, di-, or tri-halogen substitution; Ra limited to H/halo/hydroxy/C1-4alkyl).
- Dependent claims 2–9 narrow R1 to specific halogen substitution patterns, heavily centered on fluorinated phenyl isomers (2-F/4-F; multiple difluoro placements; 2,4,6-trifluoro and 2,3,4-trifluoro).
- Dependent claim 10 narrows Y1/Y2 to H/methyl/CF3.
- Claims 13–16 extend coverage into pharmaceutical compositions and into HIV combination regimens with enumerated anti-HIV classes (protease inhibitors, NNRTIs, NRTIs, nucleotide inhibitors).
- Without the patent’s full specification, drawings, and family records, a complete cross-patent landscape (related US continuations, foreign filings, litigations, FDA linkage, and Orange Book status) cannot be produced from the provided excerpt.
FAQs
1) Does US 9,732,092 cover salts and stereoisomers?
Yes. Claim 1 expressly includes stereoisomers and pharmaceutically acceptable salts of compounds having Formula (I).
2) Are CF3-containing substituents at Y1/Y2 covered?
Yes, through dependent claim 10, which permits Y1 and Y2 to be hydrogen, methyl, or trifluoromethyl (CF3).
3) What aryl halogen substitution patterns are explicitly named?
For R1: mono-halogen includes 4-fluorophenyl and 2-fluorophenyl; di-halogen includes several difluoro and fluoro-chloro phenyls; tri-halogen includes 2,4,6-trifluorophenyl and 2,3,4-trifluorophenyl, with 2,4,6-trifluorophenyl singled out again in claim 9.
4) Do the composition claims require the active to be specifically one of the enumerated compounds in claim 12?
No. Claim 13 requires a compound of claim 1 (or stereoisomer/salt). Claim 12 narrows to an enumerated group, but it is not a prerequisite for claim 13 as written.
5) Do the combination claims require the anti-HIV agent to be a specific named drug?
No. Claim 16 lists drug classes (HIV protease inhibitors, NNRTIs, NRTIs, nucleotide inhibitors) rather than specific brand-name or compound identifiers.
References (APA)
- United States Patent 9,732,092. (Claims text provided by user).
More… ↓
⤷ Start Trial
|
